Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
155.8 USD | -0.71% | +26.05% | +61.43% |
26/06 | Monetary policy is getting even more confusing | |
26/06 | Citigroup Downgrades Sarepta Therapeutics to Neutral From Buy, Raises Price Target to $176 From $172 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+61.43% | 1.48TCr | |
+16.81% | 12TCr | |
+19.99% | 12TCr | |
+21.22% | 2.66TCr | |
-23.38% | 1.99TCr | |
-17.47% | 1.63TCr | |
-45.95% | 1.55TCr | |
-18.87% | 1.55TCr | |
+3.29% | 1.37TCr | |
+118.78% | 1.11TCr |
- Stock Market
- Equities
- SRPT Stock
- News Sarepta Therapeutics, Inc.
- Sarepta Therapeutics Gets Expanded Label FDA Approval for Duchenne Muscular Dystrophy; Shares Soar Premarket